A mitochondria-targeted peptide with clinical research across mitochondrial disorders and a U.S. accelerated approval for Barth syndrome. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICSS-31 / Elamipretide
Mitochondrial HealthEnergyCellular Repair
Status
Approved
Related
3
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
LITERATURE-DERIVED REFERENCE
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Subcutaneous
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
LITERATURE-DERIVED REFERENCEU.S. Food and Drug Administration, 2025Verified 2026-09-13
Elamipretide interacts with cardiolipin-containing mitochondrial membranes and has been studied for effects on mitochondrial bioenergetics. Approval is indication-specific.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
MOTS-C
A mitochondrial-derived peptide studied in metabolic signaling, cellular stress and exercise models.
Mitochondrial HealthEnergyMetabolic
02PEPTIDE
Humanin
A mitochondrial-derived peptide studied in cellular stress, metabolism and age-associated disease models.
Mitochondrial HealthHealthy AgingCellular Repair
03PEPTIDE
NAD+
An endogenous coenzyme central to redox chemistry and cellular energy, distinct from its oral precursor compounds.